Anzemet IV Injection Withdrawn From Canadian Market Due to Potential Risk of Arrhythmias

Ottawa, ONT: Sanofi-aventis Canada Inc, in collaboration with Health Canada is informing patients of the withdrawal of ANZEMET® (dolasetron mesylate) intravenous injection as it is no longer to be used to prevent nausea and vomiting associated with chemotherapy. ANZEMET® helps prevent nausea and vomiting associated with chemotherapy.

New data show that the injectable form of ANZEMET® can potentially increase the risk of abnormal heart rhythm which may result in serious cardiac problems at the doses recommended for the prevention of nausea and vomiting. The injection form of ANZEMET® will be removed from the Canadian market as of May 10, 2011.

For further infomration about this issue, visit: http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2011/anzemet_pc-cp-eng.php

Legal Help

If you or a loved one has suffered illness or an adverse health event in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on Apr-28-11